AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 23 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A vaccine consisting of the major matrix phosphoprotein 65 (pp65) of cytomegalovirus (CMV) plus canarypox is able to stimulate pp65-specific antibody responses that are still present more than two years later, according to a report in the Journal of Infectious Diseases.
Because pp65 is an important target for cytotoxic T lymphocytes (CTLs) following natural infection, it would make an ideal vaccine candidate for CMV, proposed K. Berencsi and colleagues at Aventis Pasteur.
Their Phase I trial evaluated the canarypox-CMV pp65 recombinant in 21 CMV-seronegative volunteers who were given either vaccine or placebo at months 0, 1, 3, and 6.
After only two inoculations, the vaccine stimulated pp65-specific CTL that were still present 12 and 26 months post-vaccination.
The CTLs were phenotype CD8(+) ("A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects," J Infect Dis, April 15, 2001;183(8):1171-1179).
...